Key Takeaways ENTX unveiled promising PK data for oral GLP-2 analog OPK-8801003 in SBS.ENTX's therapy showed 15-hour half-life, 18x longer than current injection option.ENTX's oral approach could improve adherence versus burdensome daily injections.Entera Bio Ltd. (ENTX) recently reported encouraging pharmacokinetic data, underscoring the potential of its first-in-class oral GLP-2 analog therapy for patients with short bowel syndrome (SBS). The findings, presented at the 47th European Society for Clinical N ...

Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 Therapy Oral GLP-2 Tablet Could Transform Treatment Paradigm for 30,000 Short Bowel Syndrome (SBS) Patients Currently Dependent on Daily Injections of the Peptide JERUSALEM, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, today announced the presentation ...